0000000000760004

AUTHOR

Jakob Passweg

showing 4 related works from this author

Seasonal Human Coronavirus Respiratory Tract Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

2021

Abstract Background Little is known about characteristics of seasonal human coronaviruses (HCoVs) (NL63, 229E, OC43, and HKU1) after allogeneic stem cell transplantation (allo-HSCT). Methods This was a collaborative Spanish and European bone marrow transplantation retrospective multicenter study, which included allo-HSCT recipients (adults and children) with upper respiratory tract disease (URTD) and/or lower respiratory tract disease (LRTD) caused by seasonal HCoV diagnosed through multiplex polymerase chain reaction assays from January 2012 to January 2019. Results We included 402 allo-HSCT recipients who developed 449 HCoV URTD/LRTD episodes. Median age of recipients was 46 years (range,…

PNEUMONIAMalevirusesmedicine.medical_treatmentseasonal human coronavirusHematopoietic stem cell transplantationmedicine.disease_causeDISEASElaw.inventionCoronavirus OC43 HumanCLINICAL CHARACTERISTICSlawCoronavirus 229E HumanRisk FactorsImmunology and AllergyChildRespiratory Tract InfectionsNL63 INFECTIONSCoronavirusOUTCOMESRespiratory tract infectionsSYNCYTIAL VIRUSHazard ratioHematopoietic Stem Cell Transplantationvirus diseasesupper and lower respiratory tract diseaseHCoV-NL63HCoV-229Erespiratory systemMiddle AgedIntensive care unitHospitalizationimmunocompromisedsurgical procedures operativeInfectious Diseasesmedicine.anatomical_structureAcademicSubjects/MED00290Child PreschoolCohortFemaleSeasonsCoronavirus InfectionsRare cancers Radboud Institute for Health Sciences [Radboudumc 9]allogeneic hematopoietic stem cell transplantation; community-acquired respiratory virus; HCoV-229E; HCoV-HKU1; HCoV-NL63; HCoV-OC43; immunocompromised; immunodeficiency score index; multiplex PCR assay; seasonal human coronavirus; upper and lower respiratory tract diseaseAdultmedicine.medical_specialtyHCoV-OC43AdolescentDIAGNOSISCHINAHCoV-HKU1BetacoronavirusAll institutes and research themes of the Radboud University Medical Centerstomatognathic systemInternal medicinemedicineMajor ArticleRHINOVIRUSHumansallogeneic hematopoietic stem cell transplantationAgedRetrospective Studiescommunity-acquired respiratory virusbusiness.industryInfantmultiplex PCR assayTransplantationCoronavirus NL63 HumanPARAINFLUENZA VIRUSbusinessimmunodeficiency score indexRespiratory tract
researchProduct

Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion

2018

The deletion (5q) karyotype (del [5q]) in patients with myelodysplastic syndrome (MDS) is the most common karyotypic abnormality in de novo MDS. An increased number of blasts and additional karyotypic abnormalities (del [5q]+) are associated with a poor outcome. We analyzed the outcome of allogeneic hematopoietic cell transplants (HCT) in patients suffering from MDS with only del (5q) or del (5q)+ . A total of 162 patients, of median age 54 years (range, 9 to 73), having MDS and del (5q) abnormalities received HCT from identical siblings (n = 87) or unrelated donors (n = 75). The cumulative incidence of nonrelapse mortality and relapse incidence at 4 years was 29% (95% CI, 22 to 36) and 46%…

MaleBLOODDatabases FactualIMPACTCHROMOSOMECancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]medicine.medical_treatment[SDV]Life Sciences [q-bio]MedizinHematopoietic stem cell transplantationPROGNOSTIC SCORING SYSTEMGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesMDSCumulative incidenceLENALIDOMIDEIncidenceIncidence (epidemiology)Hazard ratioHematopoietic Stem Cell TransplantationHematologyMiddle AgedAllograftsTP53 MUTATIONSEUROPEAN-SOCIETY3. Good healthSurvival Rate030220 oncology & carcinogenesisWORKING PARTYChromosomes Human Pair 5FemaleChromosome DeletionLife Sciences & BiomedicineDEL(5Q)del (5q)medicine.drugAdultmedicine.medical_specialtyImmunology3122 CancersDisease-Free SurvivalSettore MED/01 - Statistica Medica03 medical and health sciencesSex FactorsAll institutes and research themes of the Radboud University Medical CenterInternal medicinemedicineHumansMARROW-TRANSPLANTATIONSurvival rateLenalidomideTransplantationScience & Technologybusiness.industryMyelodysplastic syndromesmedicine.diseaseAllogeneic stem cell transplantationTransplantationMyelodysplastic Syndromesbusiness030215 immunology
researchProduct

Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommenda…

2020

Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large- scale, clinical studies there is considerable variability in the prevention and treatment of GVHD worldwide. In 2014, to standardise treatment approaches the European Society of Blood and Marrow Transplantation published recommendations on the management of GVHD in the setting of HLA-identical sibling or unrelated donor transplantation in adult patients with haematological malignancies. Here we update these recommendations including the results of study published after 2014. Evidence was searc…

medicine.medical_specialtyTransplantation ConditioningDrug ResistanceMEDLINEGraft vs Host DiseaseBronchiolitis obliteransDisease03 medical and health sciences0302 clinical medicinegraft versus host diseasemedicineHumansDisease management (health)Intensive care medicineImmunosuppression Therapybusiness.industryDisease ManagementHematologymedicine.disease3. Good healthAnti-thymocyte globulinTransplantationSystematic reviewGraft-versus-host diseasesurgical procedures operativeHematologic Neoplasms030220 oncology & carcinogenesisDrug MonitoringbusinessImmunosuppressive AgentsStem Cell Transplantation030215 immunology
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct